Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program


You May Also Like

Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million

Sharpens Focus on Innovative ADAPTIR® Bispecific Antibody Platform and IXINITY® Commercial Asset Strengthens Cash Position ...

MPI’s spinout Oncology Venture will execute license to multi TKI phase 3 compound

Hoersholm, Denmark, January 15, 2018 - Medical Prognosis Institute A/S (MPI.ST) spinout Oncology Venture ...